A Novel Therapeutic Strategy   to Address Cancer                   September 2011
Cancer     is the leading cause of deathworldwide and accounted for 7.6 million         deaths in 2008 alone
There were 12.7 million new cases of        Cancer in 2008
Cancer deaths in the United Statesare expected to exceed 570,000 in 2011
In 2011, new cases of Cancer areexpected to exceed 1,500,000 in the U.S.
Innovative strategies are neededto address Cancer progressionmechanisms that are beyond thereach of current drug therapies
A therapeutic strategy that could inhibit theproliferation of immunosuppressive exosomesreleased by solid tumors, lymphoma...
What are Exosomes?• Cancer cells, both in vivo  and in vitro, have been  demonstrated to release  membranous structures,  ...
Researchers have recently unveiled several roles that exosomes play in accelerating             cancer progression
The resulting research publications   are reporting that................
Exosomes cause apoptosis or programmed       cell death of immune cells
Exosomes disrupt signaling of     anti-cancer T cells
Exosomes contribute to tumor angiogenesis
Exosomes enhance the spread of tumor metastasis
The quantity of exosomes in circulation is indirect correlation with cancer progression
What if exosomes could beeliminated from circulation?
The Aethlon Hemopurifier®The first therapeutic candidate to eliminate    cancer exosomes from circulation
The Aethlon Hemopurifier®• Provides a therapeutic filtration  mechanism to remove cancer  exosomes from the circulatory  sys...
Providing access to the entire          circulatory system• Exosomes can be accessed  from entire circulatory system,  whi...
Hemopurifier® therapy has the advantage of beingdelivered through the global infrastructure of dialysismachines that are al...
Our goal is to improve patient responsivenessto traditional chemotherapies and emergingclasses of immune based therapies
To improve patient responsiveness withoutadditional drug toxicity or interaction risks
In vitro binding of exosomes underlying thefollowing cancers has been demonstrated• Breast• Ovarian• Colorectal• Lymphoma•...
Human Hemopurifier® treatment   experience already exists
The Hemopurifier® has previously demonstratedthe ability to reduce viral load in HIV andhepatitis C (HCV) infected individu...
A clinical study to evaluate the ability of theHemopurifier® to improve HCV drug therapybenefit is currently being conducted
The clinical application of the  Hemopurifier® in Cancer?
We are currently collaborating withcandidate investigators to develop a clinicalprotocol to demonstrate the ability of our...
We invite you to follow our efforts    to improve cancer care      AethlonMedical.com
Our mission is to create innovative devices thataddress unmet medical needs in cancer, infectiousdisease, and other life-t...
ContactJim JoyceChairman, CEO8910 University Center LaneSan Diego, California 92122jj@aethlonmedical.com
 This presentation contains forward-looking statements within the meaning of the Private SecuritiesLitigation Reform Act o...
A Novel Therapeutic Strategy to Address Cancer
A Novel Therapeutic Strategy to Address Cancer
Upcoming SlideShare
Loading in …5
×

A Novel Therapeutic Strategy to Address Cancer

13,285 views

Published on

Introduction to a novel therapeutic strategy to inhibit exosomes that contribute to cancer progression

Published in: Health & Medicine, Business
  • Have someone make friends with me? I'm chinese man。
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here

A Novel Therapeutic Strategy to Address Cancer

  1. A Novel Therapeutic Strategy to Address Cancer September 2011
  2. Cancer is the leading cause of deathworldwide and accounted for 7.6 million deaths in 2008 alone
  3. There were 12.7 million new cases of Cancer in 2008
  4. Cancer deaths in the United Statesare expected to exceed 570,000 in 2011
  5. In 2011, new cases of Cancer areexpected to exceed 1,500,000 in the U.S.
  6. Innovative strategies are neededto address Cancer progressionmechanisms that are beyond thereach of current drug therapies
  7. A therapeutic strategy that could inhibit theproliferation of immunosuppressive exosomesreleased by solid tumors, lymphomas andleukemias would fill a significant unmetmedical need in cancer care
  8. What are Exosomes?• Cancer cells, both in vivo and in vitro, have been demonstrated to release membranous structures, defined as exosomes
  9. Researchers have recently unveiled several roles that exosomes play in accelerating cancer progression
  10. The resulting research publications are reporting that................
  11. Exosomes cause apoptosis or programmed cell death of immune cells
  12. Exosomes disrupt signaling of anti-cancer T cells
  13. Exosomes contribute to tumor angiogenesis
  14. Exosomes enhance the spread of tumor metastasis
  15. The quantity of exosomes in circulation is indirect correlation with cancer progression
  16. What if exosomes could beeliminated from circulation?
  17. The Aethlon Hemopurifier®The first therapeutic candidate to eliminate cancer exosomes from circulation
  18. The Aethlon Hemopurifier®• Provides a therapeutic filtration mechanism to remove cancer exosomes from the circulatory system• Allows selective exosome capture via unique high-mannose signatures resident on exosome surfaces
  19. Providing access to the entire circulatory system• Exosomes can be accessed from entire circulatory system, which can pass through the Hemopurifier® in as little as 15 minutes
  20. Hemopurifier® therapy has the advantage of beingdelivered through the global infrastructure of dialysismachines that are already located in hospitals in clinics
  21. Our goal is to improve patient responsivenessto traditional chemotherapies and emergingclasses of immune based therapies
  22. To improve patient responsiveness withoutadditional drug toxicity or interaction risks
  23. In vitro binding of exosomes underlying thefollowing cancers has been demonstrated• Breast• Ovarian• Colorectal• Lymphoma• Melanoma
  24. Human Hemopurifier® treatment experience already exists
  25. The Hemopurifier® has previously demonstratedthe ability to reduce viral load in HIV andhepatitis C (HCV) infected individuals without theadministration of antiviral drugs
  26. A clinical study to evaluate the ability of theHemopurifier® to improve HCV drug therapybenefit is currently being conducted
  27. The clinical application of the Hemopurifier® in Cancer?
  28. We are currently collaborating withcandidate investigators to develop a clinicalprotocol to demonstrate the ability of ourHemopurifier® to eliminate circulatingcancer exosomes
  29. We invite you to follow our efforts to improve cancer care AethlonMedical.com
  30. Our mission is to create innovative devices thataddress unmet medical needs in cancer, infectiousdisease, and other life-threatening conditions Thank You
  31. ContactJim JoyceChairman, CEO8910 University Center LaneSan Diego, California 92122jj@aethlonmedical.com
  32.  This presentation contains forward-looking statements within the meaning of the Private SecuritiesLitigation Reform Act of 1995, and Aethlon Medical intends that such forward-looking statements besubject to the safe harbor created thereby.   These statements are based on management’s currentexpectations and beliefs and are subject to a number of risks, uncertainties and assumptions that couldcause actual results to differ materially from those described.  All statements, other than statements ofhistorical fact, are statements that could be deemed forward-looking statements, including the company’sability to successfully obtain FDA and other regulatory approvals for the sale of its products, thecapability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treatdisease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and theimpact that potential ability may have on disease conditions, and the company’s ability to raise capitalwhen needed.   Some information in this presentation, or on which this presentation is based, has been obtained fromsources that Aethlon Medical, Inc., believes to be reliable and accurate.   However, it has not beenindependently verified and no representation or warranty, express or implied, is made as to the accuracyor completeness of any information obtained from third parties. Such risks and uncertainties, including those discussed above, are more fully described in the Securitiesand Exchange Commission (SEC) reports filed by Aethlon Medical, Inc., including its most recent annualreport on Form 10-K. This presentation speaks only as of its date, and the company disclaims any dutyto update the information herein. Further information is available by contacting the company or at thecompany’s website at www.aethlonmedical.com.

×